Page last updated: 2024-11-12

eremantholide c

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

eremantholide C: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID20835084
CHEBI ID181266
MeSH IDM0518071

Synonyms (9)

Synonym
(1s,3r,7z,9r,12s,13r,15r)-13-hydroxy-3,7,12-trimethyl-13-prop-1-en-2-yl-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-diene-4,11-dione
CHEBI:181266
69883-97-2
eremantholide c
6,9-epoxy-2h-1,4-dioxacyclodeca(cd)pentalene-2,7(4ah)-dione, 2a,3,5,6,11a,11b-hexahydro-3-hydroxy-2a,6,10-trimethyl-3-(1-methylethenyl)-, (2as-(2ar*,3s*,4ar*,6s*,10z,11as*,11bs*))-
6,9-epoxy-2h-1,4-dioxacyclodeca(cd)pentalene-2,7(4ah)-dione, 2a,3,5,6,11a,11b-hexahydro-3-hydroxy-2a,6,10-trimethyl-3-(1-methylethenyl)-, (2as,3r,4as,6r,10z,11ar,11br)-
nsc 669146
DTXSID801099426
(2as,3r,4as,6r,10z,11ar,11br)-2a,3,5,6,11a,11b-hexahydro-3-hydroxy-2a,6,10-trimethyl-3-(1-methylethenyl)-6,9-epoxy-2h-1,4-dioxacyclodeca[cd]pentalene-2,7(4ah)-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
furofuranOrganic heterobicyclic compounds containing a two furan rings ortho-fused to each other.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]